What you need to know about COVID-19 vaccines

Infectious disease specialist Dr. Onyema Ogbuagu answers questions about the development, safety and distribution of a vaccine.
2:53 | 11/25/20

Coming up in the next {{countdown}} {{countdownlbl}}

Coming up next:

{{nextVideo.title}}

{{nextVideo.description}}

Skip to this video now

Now Playing:

{{currentVideo.title}}

Comments
Related Extras
Related Videos
Video Transcript
Transcript for What you need to know about COVID-19 vaccines
vaccines, pfizer announced new trial results for its covid vaccine that show an efficacy F 95% with no serious side What does that mean for us going forward? Joining us now, the man who led the clinical trial at Yale, Dr. Onyema ogbuagu. Sir, thank you so much for being here. We're seeing all these good results. What do you attribute it to? We hear 90%, 95% efficacy. It sounds great. What do we attribute such good results to? 95% efficacy for vaccine is still something we celebrate in the field of infectious disease because it means that the majority of individuals who get the vaccine will be protected against the disease, which is really exciting. The phaser vaccine was novel technology using messenger rna. And so there hasn't been quite a trial consducted like this before. So sometimes the science seems great, but you're waiting for the clinical trials to have the real world test for the vaccine. I'm probably accurate if I say that most ofre surprised by just how effective it was, but that really is great news for everyone. Certainly great news for everyone, but still a lot of questions as to when everyone will be able to take this vaccine. And maybe even more importantly at what point does this vaccine actually stop the spread of covid-19? Yeah, so, that's a great question. It's been said a lot of times that vaccines don't save lives, but vaccination does. Efficacy from the trial into real world effectiveness will have to depend on a lot of LE getting the vaccination so that we can have a decent amount of population who are protected against the disease. That's exactly how we achieve herd immunity, and that could lead to really declining case numbers and the end of the pandemic. There's concerns about, you know, safety. I think the efficacy numbers are real, but, again, like many others, hopefully trusted voices out there just reassuring the public that the studies have been well designed, well conducted, and the fda will provide excellent and independent oversight and review of the vaccines so that if there is emergency use authorization or emergency approval that people can confidently roll up their sleeves, get the shot, and hopefully we get to the end of this thing. Dr. Onyema ogbuagu, that was a good pr as well. You're an infectious disease specialist but also doing some good pr. Congrats on the work you have been doing and thank you on the work that so many of you all are doing to get this vaccine and get this pandemic under control. Thanks so much. It's my pleasure. Thanks to all the participants who engaged in the trial. So many people coming together to make this hopefully a safer world to live in.

This transcript has been automatically generated and may not be 100% accurate.

{"duration":"2:53","description":"Infectious disease specialist Dr. Onyema Ogbuagu answers questions about the development, safety and distribution of a vaccine.","mediaType":"default","section":"ABCNews/GMA","id":"74398377","title":"What you need to know about COVID-19 vaccines","url":"/GMA/GMA3/video/covid-19-vaccines-74398377"}